The hidden costs of GERD: navigating treatment options amid rising healthcare burdens

Gastroesophageal reflux disease (GERD) is a prevalent condition affecting 10% to 20% of adults in Western countries and approximately 5% in Asia. With over 5.6 million physician visits annually in the U.S. alone, GERD represents a significant healthcare burden. Economic impact estimates suggest that GERD, along with its complications, incurs direct costs exceeding $18 billion annually, driven largely by the widespread use of proton pump inhibitors (PPIs). Indirect costs, including lost work productivity, are even more substantial, reaching up to $75 billion.

The condition is primarily diagnosed based on symptoms such as heartburn and regurgitation, but these symptoms can be insensitive indicators of reflux, leading to challenges in accurate diagnosis and treatment. Current management guidelines recommend PPIs as the first line of treatment, followed by endoscopy for those with persistent symptoms or alarm symptoms like dysphagia, anemia, and weight loss. PPIs have shown effectiveness in managing GERD, but up to 40% of patients experience only partial relief, prompting further investigation and, in some cases, surgical or endoscopic interventions.

GERD's pathophysiology is multifactorial, involving transient lower esophageal sphincter relaxation, obesity, delayed gastric emptying, and hiatal hernias. These factors contribute to the persistence of symptoms despite treatment, necessitating a nuanced approach to management. Lifestyle modifications, including weight loss and sleep position adjustments, are recommended alongside pharmacotherapy. In cases where medical management fails, surgical options like fundoplication and innovative endoscopic techniques are considered, although they carry risks and may not be suitable for all patients.